GlassScriptPhysician profile
Joseph Ryan Turner
NPI 1366603631
$1,769.97
in general payments reported to CMS, 2019-2025
17 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $84.32 · 2021: $137 · 2022: $292 · 2023: $109 · 2024: $300 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $335.52 | 2019-2025 | Hydrus Microstent, Luxor, Clareon Panoptix Pro |
| Glaukos Corporation | $268.23 | 2020-2023 | Photrexa Cross-Linking Kit |
| Tarsus Pharmaceuticals, INC. | $219.93 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $174.92 | 2022-2025 | Oxervate |
| Abbvie INC. | $121.53 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $102.73 | 2021-2025 | Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.74 | 2019-2021 | |
| Biotissue Holdings INC. | $86.32 | 2025 | |
| Ocular Therapeutix, INC. | $77.34 | 2023-2024 | Dextenza |
| Bausch & Lomb Americas INC. | $58.34 | 2023-2024 | Miebo, Vyzulta |
| Omeros Corporation | $56.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.39 | 2019 | |
| Sun Pharmaceutical Industries INC. | $43.59 | 2022-2024 | |
| Kala Pharmaceuticals, INC. | $31.80 | 2019 | |
| Aerie Pharmaceuticals, INC. | $25.24 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.90 | 2022 | |
| Eyevance Pharmaceuticals LLC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.